Macquarie sets JPY 7,300 target for Chugai Pharmaceutical stock

Published on 10/20/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 27, 2026. Chugai Pharmaceutical stock costs EUR 36.09 on October 20, 2026.

Pipeline data and upcoming results

Macquarie set a JPY 7,300 target for Chugai Pharmaceutical on October 16, 2026.
Vamikibart data showed that approximately two-thirds of patients needed no retreatment after Week 16.
Chugai Pharmaceutical stock traded at EUR 36.09 at 9:37 a.m. CEST at Lang & Schwarz on October 20, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) stock was trading at EUR 36.09 at Lang & Schwarz at 9:37 a.m. CEST on October 20, 2026. The latest analyst signal came from Macquarie, which maintained a Buy rating and set a JPY 7,300 price target on October 16, 2026, according to Markets Insider.

Vamikibart data add pipeline context

Chugai Pharmaceutical reported on October 13, 2026 that Roche had presented one-year Phase III data for vamikibart in uveitic macular edema. The official release said the treatment sustained improvements in vision and reduced macular thickness through Week 52, while approximately two-thirds of patients entering the as-needed dosing period after Week 16 required no retreatment, according to Chugai Pharmaceutical.

Three dates frame the stock

The recent chronology is clear. On October 13, 2026, Chugai Pharmaceutical disclosed Week 52 vamikibart data. On October 16, 2026, Macquarie set its JPY 7,300 target. On October 20, 2026, the Lang & Schwarz quote stood at EUR 36.09.

What does the target add?

Macquarie's JPY 7,300 target sits alongside a separate UBS Hold view at JPY 6,700 dated October 14, 2026, as reported by Markets Insider. The different ratings put the pipeline evidence and the October results in the foreground for the next market assessment.

Results arrive October 27

Chugai Pharmaceutical's investor-relations calendar lists fiscal 2026 third-quarter results for October 27, 2026, followed by a conference on the same date. The company identifies the reporting period as January through September 2026 on its investor-relations page, which also lists its fiscal 2026 second-quarter presentation dated July 24, 2026.

Stock price and company scale

Chugai Pharmaceutical's market capitalization was USD 65.3 billion as of October 19, 2026. The company operates in pharmaceutical research, development, manufacturing and sales, with Tokyo as its primary listing market and 4519 as its stock symbol.

Chugai Pharmaceutical stock was trading at EUR 36.09 at Lang & Schwarz on October 20, 2026 at 9:37 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.